Q: Why can endpoints in oncology trials sometimes be misleading?
One of the biggest mistakes I see is assuming a positive endpoint automatically means a treatment is a meaningful advancement for patients. However, it isn’t always that simple. Endpoints are essential because they give us a way to measure whether a therapy is working, but they only tell part of the story. Two studies can both meet their primary endpoint and leave us with very different conclusions about the real clinical significance of the treatment.
Take progression-free survival (PFS), for example. A drug may delay tumor growth by a few months, which is certainly important in many settings, but that number alone doesn’t tell us whether patients lived longer, felt better, maintained their quality of life, or experienced significant side effects along the way. The same is true for response rates. While a tumor shrinking on a scan is encouraging, but if those responses don’t last or don’t translate into better outcomes for patients, we have to ask a bigger question: what did that response actually mean?
Over years of working in oncology drug development, I’ve come to realize that the most meaningful conversations don’t happen after seeing a single number on a slide. Instead they happen when you step back and look at the entire picture. We should ask questions like: Who were the patients enrolled? How long did the benefits last? What was the safety profile? Did the treatment improve daily life, or did it simply change a statistical outcome? These are the questions that distinguish a statistically significant result from a clinically meaningful one.
Key takeaway: Endpoints are important, but they should never be interpreted in isolation. Great oncology trials not only produce positive results but they also provide evidence that those results represent a real improvement in patients’ lives. That’s the difference between a treatment that looks promising on paper and one that truly changes the standard of care.
Question for you: When you evaluate oncology trial results, which endpoint do you find most meaningful: overall survival, progression-free survival, quality of life, minimal residual disease, or something else? I’d love to hear how others think about balancing statistical success with clinical impact.